摘要:
The invention relates to the novel acid addition salts AB of the following free base of formula (A) or the enantiomer thereof with a physiologically acceptable acid B selected from the group consisting of hydrochloric acid, fumaric acid, and tartaric acid and to the polymorphs, hydrates, and solvates thereof.
摘要:
The invention relates to a method for producing betamimetics of formula (I), in which n represents 1 or 2; R1 represents hydrogen, halogen, C1-4 alkyl or O-C1-4 alkyl; R2 represents hydrogen, halogen, C1-4 alkyl or O-C1-4 alkyl, and; R3 represents hydrogen, C1-4 alkyl, OH, halogen, O-C1-4 alkyl, O-C1-4 alkylene-COOH, O-C1-4 alkylene-COO-C1-4-alkyl.
摘要:
The present invention relates to a method for producing compounds of general formula (I), in which m, n, R 1 , and R 2 are defined as described below, to enantiomers thereof, to diastereomers thereof, to mixtures thereof, and to salts thereof, in particular physiologically acceptable salts thereof having organic or inorganic acids or bases.
摘要:
The present invention relates to an improved process for manufacturing dihydropteridinones of general formula (12) as well as intermediates thereof, wherein the groups R 1 , R 2 , R 3 , R 4 , and R 5 have the meanings given in the claims and specification.
摘要:
The invention relates to a method for producing the compound 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepine-2(1H)-one of formula (I), which can be found as a structural element in CGRP antagonists that are suited especially for the oral treatment of migraine.
摘要:
The invention relates to a method for producing the compound 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepine-2(1H)-one of formula (I), which can be found as a structural element in CGRP antagonists that are suited especially for the oral treatment of migraine.
摘要:
Disclosed is a process for preparing a macrocyclic compound of the formula (I) which is carried out using an intermediate of the formula (II) wherein W, R1 through R4, D,A and R12 are as defined herein. The compounds of formula (I) are potent active agents for the treatment of hepatitis C virus (HCV) infection.